EVOLUTION OF ANDROGEN DEPRIVATION THERAPY

被引：0
|
作者：
Raj, Ganesh V. [1 ]
Selth, Luke A. [2 ,3 ]
Day, Tanya K. [2 ,3 ]
Tilley, Wayne D. [2 ,3 ]
机构：
[1] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA
[2] Univ Adelaide, Dame Roma Mitchell Canc Res Labs, Discipline Med, Adelaide, SA 5005, Australia
[3] Univ Adelaide, Sch Med, Freemasons Fdn Ctr Mens Hlth, Adelaide, SA 5005, Australia
来源：
CANCER FORUM | 2015年 / 39卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The androgen signalling axis is critical for the development and progression of prostate cancer. Therefore, the mainstay treatments for metastatic disease are hormonal manipulations aimed at reducing androgen levels and/or blocking the androgen receptor, collectively termed androgen deprivation therapy. This review will discuss the evolution of androgen deprivation therapy since it was instigated more than 70 years ago, and outline the key mechanisms underlying its inevitable failure. We will also briefly introduce potential new androgen signalling-targeted therapies in clinical development.
引用
收藏
页码：189 / 194
页数：6
相关论文
共 50 条
  • [31] Indications and Complications of Androgen Deprivation Therapy
    Fankhauser, Christian Daniel
    Wettstein, Marian Severin
    Reinhardt, Michele
    Gessendorfer, Axel
    Mostafid, Hugh
    Hermanns, Thomas
    SEMINARS IN ONCOLOGY NURSING, 2020, 36 (04)
  • [32] Androgen deprivation therapy for prostate cancer
    Sharifi, N
    Gulley, JL
    Dahut, WL
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (02): : 238 - 244
  • [33] Androgen deprivation therapy and cognitive impairment?
    Bagcchi, Sanjeet
    LANCET ONCOLOGY, 2015, 16 (07): : E314 - E314
  • [34] Androgen deprivation therapy for prostate cancer
    Bahnson, Robert
    JOURNAL OF UROLOGY, 2007, 178 (04): : 1148 - 1148
  • [35] Cardiovascular Toxicities of Androgen Deprivation Therapy
    Azariyas A. Challa
    Adam Christopher Calaway
    Jennifer Cullen
    Jorge Garcia
    Nihar Desai
    Neal L. Weintraub
    Anita Deswal
    Shelby Kutty
    Ajay Vallakati
    Daniel Addison
    Ragavendra Baliga
    Courtney M. Campbell
    Avirup Guha
    Current Treatment Options in Oncology, 2021, 22
  • [36] Bones, stones and androgen deprivation therapy
    Angel Arrabal-Polo, Miguel
    del Carmen Cano-Garcia, Maria
    Arrabal-Martin, Miguel
    HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2015, 14 (04): : 668 - 669
  • [37] Androgen deprivation therapy and BMD loss
    Katherine Sole
    Nature Clinical Practice Endocrinology & Metabolism, 2006, 2 (3): : 122 - 122
  • [38] Bones, stones and androgen deprivation therapy
    Miguel Ángel Arrabal-Polo
    María del Carmen Cano-García
    Miguel Arrabal-Martín
    Hormones, 2015, 14 (4) : 668 - 669
  • [39] Cardiovascular risk and androgen deprivation therapy
    Mina Razzak
    Nature Reviews Urology, 2012, 9 (2) : 61 - 61
  • [40] Indications and Practice With Androgen Deprivation Therapy
    Moul, Judd W.
    Kibel, Adam S.
    Roach, Mack, III
    Dreicer, Robert
    UROLOGY, 2011, 78 (05) : S478 - S481
12345